INMB · Inmune Bio, Inc.
$1.93
+0.00 (+0.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$56.34M
Shares
27.75M
Volume · Oct 2
290.24K
Avg daily vol (3M)
455.31K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.93
Open$1.97
Day$1.93–2.00
52W close$1.12–2.51
Avg vol 30d344K
Short int2.3M · 8.1% float · 7.8d
Short vol60%
Last earningsMar 31, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held Mar 31, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$18.42M
Trailing 12 months
Revenue growth YoY
+257.1%
Year over year
Operating margin
-94,766.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.7%
Year over year · more shares
Price change (1Y)
-9.4%
Trailing year
Short interest
8.1%
Latest settlement · 7.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
−9%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
58%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+56%
trailing
YTD return
+24%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.11% of float · ▲ +3.1% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
82 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+257%
Y/Y
EPS growth
+12%
Y/Y
Free cash flow
$-23.6M
Balance sheet
$5.9M
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
−9%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
58%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.11% of float · ▲ +3.1% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
82 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 58%
Range high $3
vs 200-day avg +18%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INMB
this stock
Inmune Bio, Inc.
|
$56.34M | +23.7% | +257.1% | — | 8.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INMB | -4.9% | -15.0% | +55.7% | -1.0% | +23.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -4.7% | -14.5% | +43.5% | -2.0% | +10.9% |